Drug tissue distribution: Study methods and therapeutic implications

Current Pharmaceutical Design

Volumn 11, Issue 29, 2005, Pages 3829-3845

  Lanao, J M ^a   Fraile, M A ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Drug development; Drug tissue distribution; Methods; Pharmacokinetics; Therapeutics

Indexed keywords

5 FLUOROACYL; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CAPECITABINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOSPORIN; DACTINOMYCIN; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; GANCICLOVIR; GLUCOCORTICOID; IBOGAINE; LIPOSOME; METHADONE; METHOTREXATE; MONOCLONAL ANTIBODY; MORPHINE; NEUROPEPTIDE; NEW DRUG; PRODRUG; RO 0094889; TETRYLAMMONIUM; THEOPHYLLINE; TOBRAMYCIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COMPARTMENT MODEL; COMPUTER MODEL; DEONTOLOGY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SELECTIVITY; DRUG TISSUE LEVEL; FRACTAL ANALYSIS; GENE THERAPY; HUMAN; INTERMETHOD COMPARISON; ISOLATED ORGAN; MACROMOLECULE; METHODOLOGY; MICRODIALYSIS; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIMULATION; STATISTICAL MODEL; TISSUE PERFUSION; TREATMENT OUTCOME;

ANIMALS; DRUG DESIGN; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 27744581318     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580679     Document Type: Review

References (213)

1. Eichler HG, Muller M. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998; 34: 95-9.
2. Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 1992; 23: 449-68.
3. Ross BD. Perfusion tecniques in biochemistry: a laboratory manual in the use of isolated perfused organs in biochemical experimentation. Clarendon Press, Oxford. 1972.
4. Chisholm GD, Waterworth PM, Cainan, JJ, Garrod LP. Concentration of antimicrobial agents in interstitial tissue fluid. Br Med J 1973; 1: 569-73.
5. Bergeron MG, Brousseau L. Tissue fluid pharmacokinctic models in humans and animals. Exp Mod Antimicrob Chemother 1986; 1: 71-107.
6. Lanao JM, López A, Domínguez-Gil A, Martín J, Gómez JR, Tabernero JM. Distribution kinetics of netilmicin in human blister fluids: effect of renal impairment. Biopharm, Drug Disp 1991; 12: 149-62.
7. Mazièri B, Mazièri M, Delforge J, Syrota A. Ed, New trends in pharmacokinetics. Plenum Press. New York and London. 1991.
8. Bickel MH, Raaflaub RM, Hellmüller M, Stauffer EJ. Characterization of drug distribution and binding competition by two-chamber and multi-chamber distribution dialysis. J Pharm Sci 1987; 76: 68-74,
9. Clausen J, Bickel MH. Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood. J Pharm Sci 1993; 82: 345-9.
10. Kurz H, Fischtl B. Binding of drugs to tissues. Drug Metab Rev 1983; 14: 467-510.
11. Lin JH, Sugiyama Y, Awazu S, Hanano M. In vitro and in vivo evaluation of the tissue to blood partition coefficient for physiological pharmacokinetics models. J Pharmacokin Biopharm 1982; 10: 637-47.
12. Harashima H, Sugiyama Y, Sawada Y, Iga T, Hanano M. Comparison between "in-vivo" and "in-vitro" tissue-to-plasma unbound concentration ratios (Kp, f) of quinidine in rats. J Pharm Pharmacol 1984; 36: 340-2.
13. Okudaira K, Sawada Y, Sugiyama Y, Iga T, Hanano M. Effect of quinidine on the tissue binding of digoxine in guinea-pigs. J Pharm Pharmacol 1986; 38: 137-40.
14. Shibasaki S, Kawamata Y, Nishigaki R, Umemura K. Effects of cimetidine on quinidine distribution and tissue pH in rats. J Pharmacobio-Dyn 1989; 12: 324-31.
15. Schnek DW, Pritchard JF, Hayes AHJr. Studies on the uptake and binding of propanolol by rat tissues. J Pharmacol Exp, Ther 1977; 203: 621-9.
16. Kornguth ML, Bayer WH, Kunin CM. Binding of gentannicin to subcellular fractions of rabit kidney: inhibition of spennine and other polyamines. J Antimicrob Chemother 1980; 6: 121-31.
17. Wierzba K, Sugiyama Y, Iga T, Hanano M. Kinetic study on the mechanism of tissue distribution on vinblastine. J Pharmacobio-Dyn 1988: 11: 651-61
18. Jain MK. Ed, Introduction to biological membranes. Nerwark, Delaware. 1988.
19. Woon ST, Baguley BC, Palmer BD, Fraser JD, Ching LM. Uptake of the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines. Oncol Res 2002; 13: 95-101.
20. McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 2000; 49: 453-61.
21. Reinoso RF, Navarro AS, Lanao JM. In vitro characterization of ciprofloxacin distribution in rat lung. Methods Find Exp Clin Pharmacol 1998; 20: 369-75.
22. Smith BR, Bend JR. Lung perfusion techniques for xenobiotic metabolism and toxicity studies. Methods Enzimol 1981; 77: 105-20.
23. Camus P, Coudert B, D'Athis P, Dumas M, et al. Pharmacokinetics of amiodarone in the isolated rat lung. J Pharmacol Exp Ther 1990; 254: 336-43.
24. Schneidkraudt J, Calson RW. Bacterial sepsis-induced decrease in lung vascular reactivity to 9, 11-dideoxy-11a, 9a-epoxymethano-prostaglandin F2α (U-46619) in the rat. J Pharmacol Exp Ther 1990; 253: 1171-4.
25. Reinoso RF, Sanchez-Navarro A, Lanao JM. Distribution of ciprofloxacin in the isolated rat lung in the presence and absepce of tissue oedema. Eur J Pharm Sci 1999; 8: 203-9.
26. Zarzuelo A, Sanchez-Navarro A, Lopez FG, Lanao JM. A review of the isolated kidney as an experimental model for pharmacokinetic studies. Methods Find Exp Clin Pharmacol 2000; 22: 757-63.
27. Foster KA, Weiss M, Roberts MS. Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. J Pharm Pharmacol 2002; 54: 373-82.
28. Bekersky I. Use of the isolated perfused kidney as a tool in drug disposition studies. Drug Metabolism Rev 1983; 14: 931-60.
29. Hunter E, Sloneker SD, Kostenbauder HB. Influence of chronic cigarettes smoke exposure on the uptake and efflux of imipramine in the isolated perfused rat lung. Drug Metab Dispos 1983; 11: 361-65.
30. Huang JL, Morgan DJ. Influence of perfusion flow rate on uptake and pharmacodynamics of quinidine in isolated perfused rat heart. J Pharm Sci 1994; 83: 119-23.
31. Saint-pierre MV, van den Berg D, Pang KS. Physiological modeling of drug and metabolite: disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation. J Pharmacokin Biopharm 1990; 18: 423-48.
32. De Lannoy IAM, Barker IIIF, Pang KS. Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. J Pharmacokin Biopharm 1993; 21: 395-422.
33. De Lannoy IAM, Hirayama H, Pang KS. A physiological model for renal drug metabolism: enalapril esterolysis to enalaprilat in die isolated perfused rat kidney. J Pharmacokin Biopharm 1990; 18: 651-87.
34. Krupp JL, Bernards CM. Pharmacokinetics of intrathecal oligode-oxynucleotides. Anesthesiology 2004; 100: 315-22.
35. Stagni G, Shukla C. Pharmacokinetics of methotrexate in rabbit skin and plasma after iv-bolus and iontophoretic administrations. J Control Release 2003; 93: 283-92.
36. Stolle LB, Arpi M, Jorgensen PH, Riegels-Nielsen P, Keller J. In situ gentamicin concentrations in cortical bone: an experimental study using microdialysis in bone. Acta Orthop Scand 2003; 74: 611-6.
37. Marchand S, Chenel M, Lamarche I, Pariat C, Couet W. Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. J Pharm Sci 2003; 92: 2458-65.
38. Joukhadar C, Stass H, Muller-Zellenberg U, Lackner E, Kovar F, Minar E, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003; 47: 3099-103.
39. Ståhle L, Öberg B. Pharmacokinetics and distribution, over the blood brain barrier of two acyclic guanosine analogs in rats, studied by microdialysis. Antimicrob Agents Chemother 1992; 36: 339-42.
40. Kehr J. A survey on quantitative microdialysis: theoretical models and practical implications. J Neurosci Methods 1993; 48: 251-61.
41. Herrera AM, Dennis OS, Lunte CE. Microdialysis sampling for determination of plasma protein binding of drugs. Pharm Res 1990; 7: 1077-81.
42. Rapp M, Giraud I, Maurizis JC, Galmier MJ, Madelmont JC. Synthesis and in vivo biodisposition of [14C]-quaternary ammoniummelphalan conjugate, a potential cartilage-targeted alkylating drug. Bioconjug Chem 2003; 14: 500-6.
43. Kvinnsland Y, Bruland O, Moe L, Skretting A. A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrC12 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma. Ear J Nucl Med Mol Imaging 2002; 29: 191-7.
44. Solon EG, Kraus L. Quantitative whole-body autoradiography in the pharmaceutical industry. Survey results on study design, methods, and regulatory compliance. J Pharmacol Toxicol Methods 2001; 46: 73-81.
45. Fischman AJ, Rubin RH, Strauss HW. New trends in pharmacokinetics. New York and London. Plenum Press. 1991.
46. Klimas MT. Positron emission tomography and drug discovery: contribution to the understanding of pharmacokinetics, mechanism of action and disease state characterization. Mol Imaging Biol 2002; 45: 311-37.
47. Fischam AJ, Alpert NM, Rubin RH. Pharmacokinetic imaging: a noninvasive method for determing drug distribution and action. Clin Pharmacokinet 2002; 41: 581-602.
48. Marthi K, Jakobsen S, Bender D, Hansen SB, Smith SB, Hermansen F, et al. [N-methyl-(11)C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. Psychopharmacology (Berl) 2004; 15:.
49. Wu HS, Huang WS, Liu YC, Yen RF, Shen YY, Kao CH. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan. Anticancer Res 2003; 23: 4235-8.
50. Singh M, Waluch V. Physics and instrumentation for imaging "in vivo" drug distribution. Adv Drug Deliv Rev 2000, 41. 7-20.
51. Jynge MD, Sketjne T, Gribbestad I, Kleinbloessem CH, Hoogkamer HFW, Antonsen O, Krane J, Bakoy OE, Furuheim KM, Nilsen OG. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: A study of liver and muscle disposition of fleroxacin in humans. Clin Pharmacol Ther 1990; 48: 481-89.
52. 19F NMR spectroscopy. Magn Reson Med 1998; 39(1): 149-154.
53. Kilts CD. In vivo imaging of the pharmacodynamics and pharmacokinetics of lithium. J Clin Psychiatry 2000; 61 Suppl 9: 41-6.
54. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428-38,
55. Laurivee B, Averill DA. Modulation of adriamycin cytotoxicity and transport in drug sensitive and multidrug-resistant Chinese hamster ovary cells by hyperthermia and cyclosporin A. Cancer Chemother Pharmacol 2000; 45: 219-30.
56. Wan WK, Lovich MA, Hwang CW, Edelman ER. Measurement of drug distribution in vascular tissue using quantitative fluorescence microscopy. J Pharm Sci 1999; 88: 822-9.
57. Kimura H, Mukaida M, Mori A. Detection of stimulants in hair by laser microscopy. J Anal Toxicol 1999; 23: 577-80.
58. Davies CL, Duffy PM, MacRobert AJ, Loizidiu M, Cooper AJ, Taylor I. Localization of antrhacycline accumulation in sensitive and resistant urothelial tumor cell lines, Cancer Detect. Prev 1996; 20: 625-33.
59. Davies CL, Loizidiu M, Cooper AJ, Taylor I. Effect of gammalinilenic acid on cellular uptake of structurally related antracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines. Eur J Cancer 1999; 35: 1534-40.
60. Belhoussine R, Morjani H, Manfait M. Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microespectrofluorometry. Bull Cancer 1997; 84: 343-9.
61. Villamarin S, Mansilla S, Ferrer-Miralles N, Priebe W, Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur J Biochem 2003; 270: 764-70.
62. Everts M, Koning GA, Kok RJ, Asgeirsdottir SA, Vestweber D, Meijer DK, et al. In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm Res 2003; 20: 64-72.
63. Osth K, Strindelius L, Larhed A, Ahlander A, Roomans GM, Sjoholm I, et al. Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa in vitro. J Drug Target 2003; 11: 75-82.
64. Bevill RF, Koritz GD, Dittert LW, Bourne DWA. Disposition of sulfonamides in food-producing animals. V: Disposition of sulfathiazole in tissue, urine and plasma of swine following intravenous administration. J Pharm Sci 1977; 66: 1297-300.
65. Hough LB, Bagal AA, Glick SD. Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. Methods Find Exp Clin Pharmacol 2000; 22: 77-81.
66. Rojas C, Nagaraja NV, Webb AI, Derendorf H. Microdialysis of triamcinolone acetonide in rat muscle. J Pharm Sci 2003; 92: 394-7.
67. Sandouk P, Serrie A, Urtizberea M, Debray M, Got P, Scherrmann JM. Morphine pharmacokinetics and pain assesment after intracerebroventricular administration in patients with terminal cancer. Clin Pharmacol Ther 1991; 49: 442-8.
68. Strauss WL, Layton ME, Dager SR. Characterization of human brain pharmacokinetics using a two-compartment model. Biol Psychiatry 1999; 45: 1384-8.
69. Niazi S, Chiou WL. Fluorocarbon aerosol propellants X: Pharmacokinetics of dichlorotetrafluoroethane in dogs. J Pharm Sci 1976; 65: 60-4.
70. Dahlström BE, Paalzow LK. Pharmacokinetics of morphine in plasma and discrete areas of the rat brain. J Pharmacokin Biopharm 1975; 3: 293-302
71. Chatelut E, Roche H, Plusquellec Y, Peyrille F, De Biasi J, Pujol A, et al. Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children. J Pharm Sci 1991; 80: 730-4.
72. Sonneveld P, Mulder JA. Development and identification of a multicompartment model for the distribution of adriamycin in the rat. J Pharmacokin Biopharm 1981; 9: 577-601.
73. Nakazono T, Murakami T, Skai S, Higashi Y, Yata N. Brain and cerebrospinal fluid distribution of metoprolol in rats. J Pharmacobio-Dyn 1992; 15: 295-302.
74. Noe DA, Kumor KM. Drug kinetics in low-flow (small) anatomic compartments. J Pharm Sci 1983; 72: 718-9.
75. Yamamoto T, Yasuda J, Kanao M, Okada H, Oguma T, Yamada H. A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans. Clin Pharmacokinet 1986; 11: 154-63.
76. Celardo A, Passerini F, Bonati M. Placental transfer and tissue distribution of thiopental in the pregnant rat. J Pharmacokin Biopharm 1989; 17: 425-40.
77. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modelling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71.
78. Nagashima R, Levy G, O'Reilly RA. Comparative pharmacokinetics of coumarin anticoagulants IV. Application of a three compartmental model to the analysis of the dose dependent kinetics of bishydroxicumarin elimination. J Pharm Sci 1968; 57: 1888-95.
79. Piotrovskij V, van Peer A. A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans. Pharm Res 1997; 14: 230-7.
80. Makoid MC, Robinson JR. Pharmacokinetics of topically applied pilocarpine in the albino rabbit eye. J Pharm Sci 1979; 68: 435-43.
81. Coffey JF, Bullock FJ, Schoenemann PT. Numerical solution of nonlinear pharmacokinetics equations: effects of plasma proteing binding on drug distribution and elimination. J Pharm Sci 1971; 60: 1623-8.
82. Kunka RL, Mattocks AM. Nonlinear model for acetazolamide. J Pharm Sci 1979; 68: 342-6.
83. Relling MV, Evans RR, Groom S, Crom WR, Pratt CB. Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics. J Pharm Biopharm 1993; 21: 639-51.
84. Lees KR, Kelman AW, Reid JL, Whiting B. Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J Pharmacokin Biopharm 1989; 17: 529-50.
85. Chapell MJ, Thom Bischoff KB, Dedrick RL, Zaharko DS, Long-Streth JA. Methotrexate pharmacokinetics. J. Pharm. Sci. 60: 1128-1133. 1971.
86. as G.D., Godfrey K.R., Brawell A.R. Optimal tumor targeting by antibodies: development of a mathematical model. J Pharmacokin Biopharm 1991; 19: 227-60.
87. Nestorov IA, Aarons LJ, Arundel PA, Rowland M. Lumping of whole body physiologically based pharmacokinetic model. J Pharmacokin Biopharm 1998; 26: 21-46.
88. Bonate PL, Swann A, Silverman PB. Preliminary physiologically based pharmacokinetic model for cocaine in the rat: model development and scale-up to humans. J Pharm Sci 1996; 85: 878-83.
89. Bischoff KB, Dedrick RL, Zaharko DS. Preliminary model for methotrexate pharmacokinetics. J Pharm Sci 1970; 59: 149-54.
90. Montandon B, Roberts RJ, Fischer U. Computer simulation of sulfobromophtalein kinetics in the rat using flow-limited models with extrapolation to man. J Pharmacokin Biopharm 1975; 3: 277-90.
91. Tterlikkis L, Ortega E, Solomon R, Day JL. Pharmacokinetics of mercaptopurine. J Pharm Sci 1977; 66: 1454-7.
92. Gillis PP, DeAngelis RJ, Wynn RL. Nonlinear pharmacokinetic model of intravenous anesthesia. J Pharm Sci 1976; 65: 1001-6.
93. Smith RH, Hunt DH, Seifen AB, Ferrari A, Thompson DS. Pharmacokinetic model for procaine in humans during and following intravenous infusion. J Pharm Sci 1979; 68: 1016-22.
94. Dedrick RL, Meyers CE, Bungay PM, y De Vita VT. Pharmacokinetic rationale for peritoneal drug administration treatment of ovarian cancer. Cancer Treatment Rep 1978; 62: 1-11.
95. Licata AC, Dekant W, Smith CE, Borghoff SJ. A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. Toxicol Sci 2001; 62: 191-204.
96. Fennell TR, Brown CD. A physiologically based pharmacokinetic model for ethylene oxide in mouse, rat, and human. Toxicol Appl Pharmacol 2001; 173: 161-75.
97. Upton RN, Ludbrook GL, Martinez AM, Grant C, Milne RW. Cerebral and lung kinetics of morphine in conscious sheep after short intravenous infusions. Br J Anaesth 2003; 90: 750-8.
98. Kawai R, Lemaire M, Steimer JL, Bruelisauer A, Niederberger W, Rowland M. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokin Biopharm 1994; 22: 327-65.
99. Harris PA, Gross JF. Preliminary pharmacokinetic model for adriamycin. Cance Chemother Rep 1975; 59: 819-25.
100. Mintun M, Himmelstein KJ, Schroder RL, Gibaldi M, Shen DD. Tissue distribution kinetics of tetraethylammonium ion in the rat. J Pharmacokin Biopharm 1979; 8: 373-409.
101. Dedrick RL, Zaharko DS, Lutz RJ. Transport and binding of methotrexate in vivo. J Pharm Sci 1973; 62: 882-90.
102. Lutz RJ, Dedrick RL, Straw JA, Hart MM, Klubes P, Zaharko DS. The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma. J Pharmacokin Biopharm 1975; 3: 77-97.
103. Weisbroad JM, Jain RK, Sirotnak FM. Pharmacokinetics of methotrexate in leukemia cells: effects of dose and mode of injection. J Pharmacokin Biopharm 1978; 6: 487-502.
104. Igari Y. Sugiyama Y. Awazu S, Hanano M. Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat. J Pharmacokin Biopharm 1982; 10: 53-75.
105. Blakey GE, Nestorov IA, Arundel PA, Aarons, LJ, Rowland M. Quantitative Structure-Pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokin Biopharm 1997; 25: 277-312.
106. Engasser M, Sarhan F, Falcoz C, Minier M, Letorneur P, Siest G. Distribution, metabolism, and elimination of hexobarbital in rats: Physiologically based pharmacokinetic model. J Pharm Sci 1981; 70: 1233-7.
107. Gabrielson JL, Groth T. An extended physiological pharmacokinetic model of methadone disposition in the rat: validation and sensitivity analysis. J Pharmacokin Biopharm 1988; 16: 183-201.
108. Gabrielson JL, Paalzow K, Nrdstrom L. A physiologically based pharmacokinetic model of theophylline disposition in the pregnant and nonpregnant rat. J Pharmacokin Biopharm 1988; 12: 149-65.
109. Kim CS, Sandberg JA, Slikker W, Binienda Z, Schlosser PM, Patterson TA. Quantitative exposure assessment: application of physiologically-based pharmacokinetic (PBPK) modeling of low-dose, long-term exposures of organic acid toxicant in the brain 2001; 9: 153-160.
110. Law FC, Abedini S, Kennedy CJ. A biologically based toxicokinetic model for pyrene in rainbow trout. Toxicol App] Pharmacol 1991; 110: 390-402.
111. Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 1994; 54: 5118-22.
112. Thomann RV, Snyder CA, Squibb KS. Development of a pharmacokinetic model for chromium in the rat following subchronic exposure. I. The importance of incorporating long-term storage compartment. Toxicol Appl Pharmacol 1994; 128: 189-98.
113. Nishikawa M, Yamashita F, Takakura Y, Hashida M, Sekaki H. Demonstration of the receptor-mediated hepatic uptake of dextran in mice. J Pharm Pharmacol 1992; 44: 396-401.
114. Upton RN, Ludbrook GL, Gray EC, Grant C. The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. Anesthesiology 1997; 86: 1317-25.
115. Norwich KN, Siu S. Power functions in physiology and pharmacology. J Theor Biol 1982; 95: 387-98.
116. Sung C, van Osdol WW, Saga T, Neumann RD, Dedrick RL, Weinstein JN. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res 1994;
117. Collins JM, Dedrick RL, Flessner MF, Guarino AM. Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: Experimental observations and distributed modelling. J Pharm Sci 1982; 71: 735-8.
118. Wientjes MG, Dalton JT, Badalament RA, Dasani BM, Drago JR, Au JLS. A method to study drug concentration-depth profiles in tissues: Mitomycin C in dog bladder wall. Pharm Res 1991; 8: 168-73.
119. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JLS. Penetration of Mitomycin C in human bladder. Cancer Res 1993; 53: 3314-20.
120. Gupta E, Wientjes MG, Au JLS. Penetration kinetics of 2′3′-dideoxymosine in dermis is described by the distributed model. Pharm Res 1995; 12: 108-12.
121. Blasberg RC, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after venticulocisternal perfusion 1975; 195: 73-83.
122. Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001; 85: 157-65.
123. Baxter LT, Jain RK. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer 1996; 73: 447-56.
124. Fujimori K, Fisher DR, Weinstein JN. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. Cancer Res 1991; 51: 4821-7.
125. Roberts MS,, Rowland M. A dispersion model of hepatic elimination: I. Formulation of the model and bolus considerations. J Pharmacokin Biopharm 1986; 14: 227-60.
126. Yano Y, Yamaoka K, Minamide T, Nakagawa T, Tanaka H. Evaluation of protein binding effect on local disposition of oxacillin in rat liver by a two-compartment dispersion model. J Pharm Pharmacol 1990; 42: 632-6.
127. Evans AM, Hussein Z, Rowland M. Influence of albumin on the distribution and elimination kinetics of diclofenac in the isolated perfused rat liver: analysis by the impulse-response technique and the dispersion model. J Pharm Sci 1993; 82: 421-8.
128. Hussein Z, Evans AM, Rowland M. Physiologic models of hepatic drug clearance: Influence of altered protein binding on the elimination of diclofenac in the isolated perfused rat liver. J Pharm Sci 1993; 82: 880-5.
129. Chow CH, Rowland M. Effect of altered tissue binding on the disposition of barbital in the isolated perfused rat liver: application of the axial dispersion model. J Pharm Sci 1997; 86: 1310-4.
130. Oliver RE, Heatherington AC, Jones AF, Rowland M. A physiologically based pharmacokinetic model incorporating dispersion principles to describe solute distribution in the perfused rat hindlimb preparation. J Pharmacokin Biopharm 1997; 25: 389-412.
131. Mandelbrot BB. Ed, The fractal geometry of nature. W.H. Freeman, San Francisco. 1982.
132. Macheras P. Carrier-mediated transport can obey fractal kinetics. Pharm Res 1995; 12: 541-8.
133. Macheras P. A fractal approach to heterogeneous drug distribution: calcium pharmacokinetics. Pharm Res 1996; 13: 663-70.
134. Dokoumetzidis A, Macheras P. A model for transport and dispersion in the circulatory system based on the vascular fractal tree. Ann Biomed Eng 2003; 31: 284-93.
135. Wise ME. Negative power functions of time in Pharmacokinetics and their implications. J Pharmacokin Biopharm 1985; 13: 309-46.
136. Pfeffer M. Gamma variate fits to pharmacokinetic data. Eur J Drug Met Pharm 1988; 13: 155-159.
137. Goans RE, Abrams SA, Vieira NE, Marini JC, Perez MD, Yergey AL. A three-hour measurement to evaluate bone calcium turn-over. Bone 1995; 16: 33-8.
138. El-Masri HA, Thomas RS, Benjamin SA, Yang RS. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. Toxicology 1995; 105: 275-82.
139. Diamond GL, Thayer WC, Choudbury H. Pharmacokinetics/pharmacodynamics (PK/PD) modeling of risks of kidney toxicity from exposure to cadmium: estimates of dietary risks in the U.S. population. J Toxicol Environ Health A 2003; 66: 2141-64.
140. Van Rossum JM, de Bie JEGM, van Liegen G, Teauwen HWA. Pharmacokinetics from a dynamical point of view. J Pharmacokin Biopharm 1989; 17:365-92.
141. Veng-Pedersen P, Gillespie WR. Single pass mean residence time in peripheral tissues. A distribution parameter intrinsic to the tissue affinity of a drug. J Pharm Sci 1986; 75: 1119-26.
142. Chow AT, Jusko WJ. Application of moment analysis to nonlinear drug disposition described by the Michaelis-Menten equation. Pharm Res 1987; 4: 59-61.
143. Cheng H., Yu C, Jusko WJ. An algorithm and computer program for calculating the mean transit time and distribution rates parameters of generated metabolites undergoing linear tissue distribution and linear or non linear central elimination. Biopharm Drug Dispos 1994; 15: 273-94.
144. Nakashima E, Benet LZ. An integrated approach to pharmacokinetic analysis for linear mammilary systems in which input and exit may occur in/from any compartment. J Pharmacokin Biopharm 1989; 17: 673-86.
145. McNamara PJ, Fleishaker JC, Hayden TL. Mean residence time in peripheral tissue. J Pharmacokin Biopharm 1987; 15: 439-50.
146. Kong AN, Jusko WJ. Definitions and applications of mean transit and residence times in reference to the two-compartment mammillary plasma clearance model. J Pharm Sci 1988; 77: 157-65.
147. Kakutani T, Yamaoka K, Hashida M, Sezaki H. A new method for assesment of drug disposition in muscle: application of statistical moment theory to local perfusion systems. J Pharmacokin Biopharm 1985; 13: 609-31.
148. 3H] dynorphin (1-13) in the perfused rat lung: an application of the multiple-indicator dilution method. J. Pharm. Pharmacol 1990; 42: 879-82.
149. Fraile MA, Lanao JM, López FG, Gascón AR, Martínez M, Domínguez-Gil A. Distribution kinetics of roxithromycin in isolated lung of the rat. Pharm Sci 1995; 1: 315-9.
150. Aiba T, Itoga Y, Shimizu H, Tanigawara Y, Hori R. Renal handling of tobramycin in the isolated perfused ratkidney. J Pharm Sci 1994; 83: 723-6.
151. Yasui H, Yamaoka K, Nishimura M, Naito S, Nakawara T. Moment analysis of hepatic local disposition of allopurinol to oxipurinol in the rat isolated perfused liver. J Pharm Pharmacol 1994; 46: 524-7
152. Yoshida M, Mahato RI, Kawabata K, Takakura Y, Hashida M. Disposition characteristics of plasmid DNA in the single pass rat liver perfusion system. Pharm Res 1996; 13: 599-603.
153. Kakutani T, Nara E, Hashida M. Statistical moments and disposition parameters in a local perfusion system under mammillary nonequilibrium condition. J Pharmacokin Biopharm 1990; 18: 449-58.
154. Wong J, Kuu WY, Burke R, Johnson R, Wood RW. Comparison of simulated and in-vivo plasma levels of cilastatin following intravenous in-line drug administration. Pharm Res 1995; 12: 144-8.
155. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther 1994; 268: 144-51.
156. Van Bree JBMM, Baljet AV, van Geyt A, de Boer AG, Danhof M, Breimer DD. The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into central nervous system. J. Pharmacokin Biopharm 1983; 17: 441-62.
157. Karol MD, Veng-Pedersen P, Brashear RE. Diffusion and flow transfer of theophylline across the blood-brain barrier: pharmacokinetic analysis. J Pharmacokin Biopharm 1983; 11: 273-87.
158. Szabo Z, Ravert HT, Gozükara I, Geckle W, Seki C, Sostre S, et al. Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse 1993; 15: 263-75.
159. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 2003; 3: 1125-54.
160. Butina D, Segall MD, Frankcombe K. Predicting ADME properties in silico: methods and models. Drug Discov Today. 2002; (11 Suppl): S83-8.
161. Eddershaw PJ, Beresford AP, Bayliss MK. ADME/PK as part of a rational approach to drug discovery. Drug Discov Today 2000; 5: 409-14.
162. Boobis A, Gundert-Remy U, Kremers P, Macheras P, Pelkonen O. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur. J. Pharm. Sci 2002; 17: 183-193.
163. Van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2003; 2: 192-204.
164. Crivori P, Cruciani G, Carrupt PA, Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem 2000; 43: 2204-16.
165. Kaznessis YN, Snow ME, Blankley CJ. Prediction of blood-brain partitioning, using Monte Carlo simulations of molecules in water. J. Comput. Aid. Mol. Des 2001; 15: 697-708.
166. Ooms F, Weber P, Carrupt PA, Testa BA. A simple model to predict blood-brain barrier permeation from 3D molecular fields. Biochim. Biophys. Acta 2002; 1587: 118-125.
167. Feher M., Sourial E, Schmidt JM. A simple model for the prediction of blood-brain partitioning. Int. J. Pharmaceut. 2000 201: 239-47.
168. Theil FP, Guentert TW, Haddad S, Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett 2003; 138: 29-49.
169. Warhurst DC, Craig JC, Adagu IS, Meyer DJ, Lee SY. The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids. Malar J 2003,2: 26.
170. Schuhmann G, Fichtl B, Kurz H. Prediction of drug distribution in vivo on the basis of in vitro binding data. Biopharm Drug Disp 1987; 8: 73-86.
171. Pan C, Cardarelli PM, Nieder MH, Pickford LB, Gangwar S, King DJ, et al. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD 10+ tumors. Cancer Res 2003; 63: 5526-31.
172. Senter PD, Svensson HP. A summary of monoclonal antibody-enzyme/prodrug. Advan. Drug. Deliver. Rev 1996; 22: 341-9.
173. Ref ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit. Rev. Oncol/Hematol 2001; 40: 25-35.
174. Hattori K, Kohchi Y, Oikawa N, Suda H, Ura M, Ishikawa T, et al. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine. Bioorg Med Chem Lett 2003; 13: 867-72.
175. Lansiaux A, Tanious F, Mishal Z, Dassonneville L, Kumar A, Stephens CE, et al. Distribution of furamidine analogues in tumor cells:
176. Tirucherai GS, Dias C, Mitra AK. Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocul Pharmacol Ther 2002; 18: 535-48.
177. Macdonald GJ, Branch CL, Hadley MS, Johnson CN, Nash DJ, Smith AB, et al. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1, 2, 4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist. J Med Chem 2003; 46: 4952-64.
178. Price CI, Horton JW, Baxter CR. Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics. Surgery 1994; 115: 480-7.
179. Marier JF, Brazier JL, Lavigne J, Ducharme MP. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003; 52: 247-52.
180. Marier JF, Lavigne J, Ducharme MP. Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection. Antimicrob Agents Chemother 2002; 46: 3776-81.
181. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994; 14: S3-7.
182. Adler-Moore I, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49: 21-30.
183. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4: 179-85.
184. Ito T, Hagiwara A, Takagi T, Fujiyama J, Sonoyama Y, Shimomura K, et al. Local administration of methotrexate bound to activated carbon particles (MTX-CH) for treating cancers in mice. Anticancer Res 2003; 23: 1401-4.
185. Nakase Y, Kin S, Fukuda K, Takagi T, Shimomura K, Ito T, et al. Intratumoral administration of methotrexate bound to activated carbon particles (MTX-CH) inducing antitumor effect in vivo. Gan To Kagaku Ryoho. 2003 Oct; 30(11): 1859-61.
186. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002; 10: 539-48.
187. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42(5): 419-36.
188. Travitzky M, Libson E, Nemirovsky I, Hadas I, Gabizon A. Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma. Anticancer Drugs 2003; 14: 247-50.
189. Lyass O, Hubert A, Gabizon AA. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 2001; 7: 3040-6,
190. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11: 1029-33.
191. Lemaire L, Roullin VG, Franconi F, Venier-Julienne MC, Menei P, Jallet P, et al. Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study. NMR Biomed 2001; 14: 360-6.
192. Roullin VG, Deverre JR, Lemaire L, Hindre F, Venier-Julienne MC, Vienet R, et al. Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm 2002; 53: 293-9.
193. Roullin VG, Lemaire L, Venier-Julienne MC, Faisant N, Franconi F, Benoit JP. Release kinetics of 5-fluorouracil-loaded microspheres on an experimental rat glioma. Anticancer Res 2003; 23: 21-5.
194. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003; 126: 1895-904.
195. Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 2003; 44: 2702-7.
196. Gutierrez MC, Sayalero ML, Zarzuelo A, Lanao JM. Drug, enzyme and peptide delivery using erythrocites as carriers. J Control Rel 2004; 95: 27-49.
197. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16: 595-609.
198. March KL, Madison JE, Trapnell BC. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by ploxamer 407 and implications for cardiovascular gene therapy. Hum. Gen. Ther 1995; 6: 41-53.
199. Markus R, Reutens DC, Kazui S, Read S, Wright P, Chambers BR, et al. Topography and temporal evolution of hypoxic viable tissue identified 18F-fluromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 2003; 34: 2646-52.
200. Arano Y, Wakisaka K, Ohmono Y, Uezono T, Akizawa H, Nakayama M, et al. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications. Bioconjug Chem 1996; 7: 628-37.
201. Stein R, Blumenthal R, Sharkey RM, Goldenberg DM. Comparative biodistribution and radioimmunotherapy of monoclonal anti-body RS7 and its F(ab′)2 in nude mice bearing human tumor xenografts. Cancer 1994; 73: 816-23.
202. Hnatowich DJ, Chinol M, Siebecker DA, Gionet M, Griffin T, Doherty PW, et al. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. J Nucl Med 1988; 29: 1428-35.
203. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002; 54: 715-58.
204. El-Aneed, A. An overview of current delivery systems in-cancer gene therapy J. Control. Rel 2004; 94: 1- 14.
205. Barth RF. A critical assessment of boron neutron capture therapy: an overview. Journal of Neuro-Oncology 2003; 62: 1-5.
206. Kabalka GW, Nichols TL, Smith GT, Miller LF, Khan MK, Busse PM. The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J. Neurooncol 2003; 62: 187-195.
207. Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J. Control. Rel 2003; 91: 123-33.
208. Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol. Res 1995; 7: 237-43.
209. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Cuff Cancer Drug Targets 2003; 3: 437-32.
210. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res 2000; 17: 1494-502.
211. Erdei A, Prechl J, Isaak A, Molnar E. Regulation of B-cell activation by complement receptors CD21 and CD35. Curr Pharm Design 2003; 9(23): 1849-60.
212. Morris-Natschke SL, Ishaq KS, Kucera LS. Phospholipid analogs against HIV-1 infection and disease. Curr Pharm Design 2003; 9(18): 1441-51.
213. Workman P. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Design 2003; 9(11): 891-902.